
Opinion|Videos|February 18, 2025
Adoption of New Treatments for BCG-Unresponsive NMIBC
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how the ability to administer newer non–muscle-invasive bladder cancer (NMIBC) treatments in local urology practices rather than specialized oncology centers reduces patient burden and travel requirements while suggesting that increased education and support could help more health care providers adopt these treatment options.
Advertisement
Episodes in this series

- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss the overall burden on patients, systemic adverse effects, and the need to travel to specialized centers.
- What strategies would you recommend to encourage more health care practitioners to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5








